

2022 Guide to Cell & Gene Therapy







Overview


The Cell & Gene Therapy market is coming off of a record growth year in 2021, seeing \$14B (USD) in funding in just the first 6 months, contributing to a total of \$19.96 for the year.

Growth factors such as cash injections, M&A, expanding applications for CGTs, rapid technological advancements, and facility expansions have catalyzed this dynamic sector of the life sciences industry.

While the number of opportunities is vast, smaller patient pools demand accelerated drug development timelines, effectively narrowing the window of opportunity for service providers to establish new partnerships.

Zymewire's **Guide to Cell & Gene Therapy** will help you optimize your approach to selling into this unique market by highlighting emerging CGT companies and equipping you with the information you need to get a step ahead and stay there.

On each page, we highlight **five companies** and reveal information about their team size, recent fundraising, hiring plans, and IND-enabling studies.





Cell Therapy Companies



Affini-T Therapeutics (WA, US)

Unlocking the power of T cells against oncogenic driver mutations.



Seeking a Principal scientist with CMO tech transfer experience



Senti Biosciences (CA, US)

Leveraging cutting-edge synthetic biology technology to develop novel therapeutics.



Plans to submit an IND application in 2023



TC BioPharm (Scotland)

Developing cell therapy products for the treatment of cancer, as well as T cell therapies for the treatment of infectious disease.



Co-Founder will be speaking at Allogeneic Cell Therapies Summit 2022



Brooklyn Immunotech (NY, US)

Boldly developing novel therapeutics utilizing mRNA-based cell engineering and complex cytokines.



Established a new R&D facility for the advancement of cellular medicines



Mustang Bio (MA, US)

Translating today's medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases.



Hiring a CMO project manager



Gene Therapy Companies



Metagenomi (ca, us)

Developing next-generation therapies through gene-editing systems.



Funds will be used to accelerate gene-editing programs through preclinical development



Spotlight Therapeutics (CA, US)

Developing a new class of biologics, Targeted Active Gene Editors (TAGE).



Looking to hire a scientist to identify and manage CDMO/CRO partners



Jaguar Gene Therapy (IL, US)

Accelerating breakthroughs in gone therapy for patients suffering from severe genetic diseases.



Opening new facility in NC to kickstart IND-enabling studies for their preclinical pipeline



Copernicus Therapeutics (OH, US)

Developing novel AAV therapies leveraging compacted nanoparticle delivery systems



Funds will be put towards advancing lead gene therapy programs into clinical trials



hC Bioscience (MA, US)

Pioneers in protein editing using gene and context agnostic tRNA



Funding will be put towards advancing their lead programs (PTCX & SVVTX) into the clinic



The platform



Make Salesforce work for you

Keep your Salesforce up-to-date with one click: add targets or update current prospects with the latest information about activities, funding, and future plans.



Relevant industry intel

Get the information you need to unveil new sales opportunities in your specific target markets pushed right to your phone.



Map your universe

Understand how well you're penetrating a given region - and make your sales trips more productive by identifying additional prospects in your target market.



Verified contact search

Immediately access the contact information of key decision-makers, so you can reach out first when breaking news happens.



Plan, delegate, assess

As a manager, plan and delegate to your team based on the most up-to-date information about your target markets. Stay ahead of the curve by measuring your team's progress and making adjustments in real time.





Thank you

Contact Us

- hello@zymewire.com
- (US) 1-844-996-3321 X 2 (UK) +44-208-133-9963 X 2

